Full year revenues expected to treble at Retroscreen Virology Group
AIM-listed Viral challenge and virometrics specialist Retroscreen Virology Group has published a trading update ahead of its year-end predicting a significant rise in its year-on-year revenues.
AIM-listed Viral challenge and virometrics specialist Retroscreen Virology Group has published a trading update ahead of its year-end predicting a significant rise in its year-on-year revenues.
The company expects to report sales for the year ending December 31st 2012 in excess of £13m compared to £4.27m for the twelve months until December 31st 2011. Gross margin and net loss are also expected to be ahead of market expectations.
The trading update published by the company stated that significant revenue growth was being achieved from Retroscreen's solid pipeline of Viral Challenge Model (VCM) client engagements.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
More specifically, it added that: "The revenue growth is principally due to the increased number of quarantines conducted during 2012, together with the study set-up and volunteer recruitment for a number of new VCM engagements with quarantines due to commence in 2013."
Kym Denny, Chief Executive Officer at Retroscreen Virology Group, commented, "I am thrilled by our revenue growth and delivery against a robust VCM pipeline, which continues to build steadily with clients holding firm against their VCM quarantine reservations booked months ahead."
Denny added: "Retroscreen remains focussed on revenue growth, developing capacity and pioneering the VCM as a new way to conducting clinical trials in the development of drugs against virus. We are building solid foundations to scale our growth and it is tremendously fulfilling to see that the outcome of this investment will be reported in our 2012 financial results."
Retroscreen Virology Group's share price rose 8.16% to 132.50p at 09:17 on Wednesday morning.
MF
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
How much should I have in emergency savings?
When your boiler breaks or your car won’t start, you can find yourself paying a hefty bill. How much should you have in emergency savings to cover unexpected costs?
By Katie Williams Published
-
ISA investments by age: should I invest more in my stocks and shares ISA?
Stocks and shares ISAs are a great way to grow long-term wealth, but are they overlooked compared to cash savings? We look the average ISA investment by age and if you should have more.
By Dan McEvoy Published